Journal article
Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
- Khanna D Department of Medicine, University of Michigan, Ann Arbor, MI, 48105, USA. khannad@umich.edu.
- Clements PJ Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
- Volkmann ER Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
- Wilhalme H Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
- Tseng CH Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
- Furst DE Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
- Roth MD Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
- Distler O Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.
- Tashkin DP Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
- 2019-01-18
Published in:
- Arthritis research & therapy. - 2019
Interstitial lung disease
Minimal clinically important difference
Modified Rodnan skin score
Scleroderma
Skin thickness
Systemic sclerosis
Adult
Antineoplastic Agents
Cyclophosphamide
Female
Humans
Lung Diseases
Male
Middle Aged
Minimal Clinically Important Difference
Mycophenolic Acid
Outcome Assessment, Health Care
Scleroderma, Diffuse
Scleroderma, Systemic
Severity of Illness Index
Skin
Surveys and Questionnaires
Time Factors
English
OBJECTIVE
This study aimed to assess the minimal clinically important differences (MCIDs) for the modified Rodnan skin score (mRSS) using combined data from the Scleroderma Lung Studies (I and II).
METHODS
MCID estimates for the mRSS at 12 months were calculated using three anchors: change in scores on the Health Assessment Questionnaire- Disability Index from baseline to 12 months, change in scores on the Patient Global Assessment from baseline to 12 months, and answer at 12 month for the Short Form-36 health transition question "Compared to one year ago, how would you rate your health in general now?" We determined the mRSS MCID estimates for all participants and for those with diffuse cutaneous systemic sclerosis (dcSSc). We then assessed associations between MCID estimates of mRSS improvement and patient-reported outcomes, using Student's t test to compare the mean differences in patient outcomes between those who met the MCID improvement criteria versus those who did not meet the improvement criteria.
RESULTS
The mean (SD) mRSS at baseline was 14.75 (10.72) for all participants and 20.93 (9.61) for those with dcSSc. The MCID estimate for mRSS improvement at 12 months ranged from 3 to 4 units for the overall group (improvement of 20-27% from baseline) and was 5 units for those with dcSSc (improvement of 24% from baseline). Those who met the mRSS MCID improvement criteria had statistically significant improvements in scores on the Short Form-36 Physical Component Summary, the Transition Dyspnea Index, and joint contractures at 12 months.
CONCLUSION
MCID estimates for the mRSS were 3-4 units for all participants and 5 units for those with dcSSc. These findings are consistent with previously reported MCID estimates for systemic sclerosis.
This study aimed to assess the minimal clinically important differences (MCIDs) for the modified Rodnan skin score (mRSS) using combined data from the Scleroderma Lung Studies (I and II).
METHODS
MCID estimates for the mRSS at 12 months were calculated using three anchors: change in scores on the Health Assessment Questionnaire- Disability Index from baseline to 12 months, change in scores on the Patient Global Assessment from baseline to 12 months, and answer at 12 month for the Short Form-36 health transition question "Compared to one year ago, how would you rate your health in general now?" We determined the mRSS MCID estimates for all participants and for those with diffuse cutaneous systemic sclerosis (dcSSc). We then assessed associations between MCID estimates of mRSS improvement and patient-reported outcomes, using Student's t test to compare the mean differences in patient outcomes between those who met the MCID improvement criteria versus those who did not meet the improvement criteria.
RESULTS
The mean (SD) mRSS at baseline was 14.75 (10.72) for all participants and 20.93 (9.61) for those with dcSSc. The MCID estimate for mRSS improvement at 12 months ranged from 3 to 4 units for the overall group (improvement of 20-27% from baseline) and was 5 units for those with dcSSc (improvement of 24% from baseline). Those who met the mRSS MCID improvement criteria had statistically significant improvements in scores on the Short Form-36 Physical Component Summary, the Transition Dyspnea Index, and joint contractures at 12 months.
CONCLUSION
MCID estimates for the mRSS were 3-4 units for all participants and 5 units for those with dcSSc. These findings are consistent with previously reported MCID estimates for systemic sclerosis.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.1186/s13075-019-1809-y
- PMID 30651141
- Persistent URL
- https://sonar.ch/global/documents/298647
Statistics
Document views: 34
File downloads: